Industry highlights: switching from manual to automated hematopoietic stem cell (HSC) gene engineering
Sponsor
Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.
Genetic modification of CD34+ cells offers a promising approach for treating inherited disorders such as sickle cell disease, ß-thalassemia, and primary immunodeficiencies. Current manufacturing processes are often manual, involving significant handling and user interaction, which increases the risk of human error. Looking ahead to clinical trials and therapeutic applications, transitioning to an automated manufacturing process early can minimize user intervention and reduce clean room requirements. This shift leads to more reproducible and standardized manufacturing processes, ultimately resulting in safer cell products.
In this webinar, Ana Rubio from Orchard Therapeutics will provide valuable insights into transitioning from manual to automated hematopoietic stem cell gene engineering using the CliniMACS Prodigy® HSC Engineering process. She will also present data from a case study highlighting the benefits of this transition.
Attend this webinar to:
- Learn about the CliniMACS Prodigy® HSC Engineering process, which automates viral transduction of HSCs
- Discover how to transition from manual to automated HSC gene engineering
- Understand common challenges in automation and how to overcome them
SPEAKERS
You might also like
Ex vivo engineering of hematopoietic stem cells using RNA-LNPs for cell and gene therapies
Integrated plasmid engineering and manufacturing process: a unified approach from lab to clinic
Case study: developing an ex vivo gene-modified hematopoietic stem cell treatment for a rare monogenic disease in a novel mouse model
